The latest price target for INmune Bio (NASDAQ:INMB) was reported by Scotiabank on August 22, 2024. The analyst firm set a price target for $22.00 expecting INMB to rise to within 12 months (a possible 303.67% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for INmune Bio (NASDAQ:INMB) was provided by Scotiabank, and INmune Bio initiated their sector outperform rating.

There is no last upgrade for INmune Bio

The last downgrade for INmune Bio Inc happened on May 24, 2022 when B. Riley Securities changed their price target from $14 to $7 for INmune Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of INmune Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for INmune Bio was filed on August 22, 2024 so you should expect the next rating to be made available sometime around August 22, 2025.

While ratings are subjective and will change, the latest INmune Bio (INMB) rating was a initiated with a price target of $0.00 to $22.00. The current price INmune Bio (INMB) is trading at is $5.45, which is within the analyst’s predicted range.